drugset / Trial / NCT01612078

Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients

NCT01612078

Phase 3 Terminated 25 enrolled TSH Biopharm Corporation Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Orthostatic hypotension is a major complication of hemodialysis and interferes with everyday activities in hemodialysis patients. Since information regarding the use of droxidopa in clinical trials relating to orthostatic hypotension of chronic hemodialysis patients is limited in Taiwan, this study is designed for evaluation the efficacy and safety profile of droxidopa on orthostatic hypotension treatment / prevention in hemodialysis patients.

Timeline

Start
2012-06
Primary completion
2013-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Droxidopa Small molecule 400 mg Oral